Orebriton (Ticagrelor)

Ticagrelor, the active ingredient in Orebriton, is a P2Y12 receptor antagonist presented as a oral tablet for oral use. It treats acute coronary syndrome and helps prevent thrombotic cardiovascular events in patients with a history of myocardial infarction. GNH USA supplies Orebriton as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orebriton is indicated for antiplatelet therapy in cardiovascular disease pathways. - Acute coronary syndrome (ACS): Reduces the risk of cardiovascular death, myocardial infarction and stroke. - Post‑myocardial infarction secondary prevention: Decreases the likelihood of recurrent ischemic events. - Long‑term secondary prevention after a prior myocardial infarction: Helps maintain arterial patency and lowers future event rates.

Ticagrelor may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dyspnea: A short‑term the    - Headache   - Nausea - Diarrhea - Bruising or minor bleeding - Elevated liver enzymes

Serious or Rare Side Effects: - Severe bleeding (intracranial, gastrointestinal) - Thrombotic thrombocytopenic purpura 

t  

When ​   a   a